Open main menu

Pages with the most revisions

Showing below up to 500 results in range #1 to #500.

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

  1. ICRP Glossary‏‎ (267 revisions)
  2. Application of ionising radiation in healthcare‏‎ (98 revisions)
  3. Information for healthcare providers‏‎ (80 revisions)
  4. Information for patients, family members, carers and the public‏‎ (62 revisions)
  5. System Of Radiation Protection Overview‏‎ (43 revisions)
  6. Guide to Radiological Protection in Healthcare‏‎ (43 revisions)
  7. General Information on Radon‏‎ (31 revisions)
  8. Main Page‏‎ (29 revisions)
  9. Application of ionising radiation in healthcare (old)‏‎ (24 revisions)
  10. Information for healthcare providers (old)‏‎ (24 revisions)
  11. Information for patients, family members, carers and the public (old)‏‎ (24 revisions)
  12. Radon For Governments and Employers‏‎ (23 revisions)
  13. Effective dose‏‎ (23 revisions)
  14. Radon For Homeowners and Residents‏‎ (22 revisions)
  15. The System of Radiological Protection‏‎ (21 revisions)
  16. Guide to Radon‏‎ (19 revisions)
  17. Tissue weighting factor‏‎ (17 revisions)
  18. List of ICRP Publications on Radiological Protection in Healthcare‏‎ (16 revisions)
  19. ICRP publications‏‎ (14 revisions)
  20. System of radiation protection module 2‏‎ (14 revisions)
  21. Quotes from Publications on the System of Radiological Protection‏‎ (13 revisions)
  22. Equivalent dose‏‎ (11 revisions)
  23. Absorbed, Equivalent, and Effective Dose‏‎ (10 revisions)
  24. Objectives of Radiological Protection‏‎ (9 revisions)
  25. Air-kerma rate constant‏‎ (9 revisions)
  26. Fundamental Principles of Radiological Protection‏‎ (9 revisions)
  27. Absorbed dose‏‎ (9 revisions)
  28. Effects of Exposure‏‎ (8 revisions)
  29. Prudence‏‎ (8 revisions)
  30. Beneficence‏‎ (8 revisions)
  31. Organ/tissue absorbed dose‏‎ (8 revisions)
  32. Collective effective dose‏‎ (7 revisions)
  33. Exposure Categories and Situations‏‎ (6 revisions)
  34. Investigation level‏‎ (6 revisions)
  35. Alimentary tract‏‎ (6 revisions)
  36. ICRPædia Guides‏‎ (6 revisions)
  37. Justice‏‎ (6 revisions)
  38. Linear energy transfer‏‎ (6 revisions)
  39. Accelerated fractionation‏‎ (6 revisions)
  40. Radiation weighting factor‏‎ (5 revisions)
  41. Air-kerma, entrance surface‏‎ (5 revisions)
  42. Sources of Radiation Exposure‏‎ (5 revisions)
  43. Dose coefficient‏‎ (5 revisions)
  44. Quality factor‏‎ (5 revisions)
  45. Principle of optimisation‏‎ (5 revisions)
  46. ICRPædia Guide to the System of Radiological Protection‏‎ (5 revisions)
  47. Absorbed fraction‏‎ (5 revisions)
  48. Justification‏‎ (5 revisions)
  49. Kerma‏‎ (5 revisions)
  50. Protection quantities‏‎ (5 revisions)
  51. Types of materials‏‎ (5 revisions)
  52. Reference Animal and Plant‏‎ (4 revisions)
  53. Kp index‏‎ (4 revisions)
  54. Protective action‏‎ (4 revisions)
  55. Source-related assessment‏‎ (4 revisions)
  56. Forbiddenness‏‎ (4 revisions)
  57. Aerodynamic diameter‏‎ (4 revisions)
  58. ICRP‏‎ (4 revisions)
  59. Reference bioassay function‏‎ (4 revisions)
  60. Diagnostic reference level‏‎ (4 revisions)
  61. Risk‏‎ (4 revisions)
  62. Senescence‏‎ (4 revisions)
  63. Air-kerma, product‏‎ (4 revisions)
  64. Fractionation sensitivity‏‎ (4 revisions)
  65. Optimisation‏‎ (4 revisions)
  66. Sievert‏‎ (4 revisions)
  67. Air kerma at the patient entrance reference point‏‎ (4 revisions)
  68. S coefficient (radiation weighted)‏‎ (4 revisions)
  69. Non-maleficence‏‎ (4 revisions)
  70. High linear energy transfer radiation‏‎ (4 revisions)
  71. Direct bioassay‏‎ (4 revisions - redirect page)
  72. Bioassay‏‎ (4 revisions)
  73. Calculating Radon Doses‏‎ (4 revisions)
  74. Computed tomography dose index‏‎ (4 revisions)
  75. Mass median diameter‏‎ (4 revisions)
  76. Alpha decay‏‎ (4 revisions)
  77. Effective charge number‏‎ (4 revisions)
  78. Math‏‎ (4 revisions)
  79. Programmed cell death‏‎ (4 revisions)
  80. Effective half-life‏‎ (4 revisions)
  81. Averted dose‏‎ (4 revisions)
  82. DS02‏‎ (3 revisions)
  83. Fluoroscopically guided interventions‏‎ (3 revisions)
  84. Annual dose‏‎ (3 revisions)
  85. Potential exposure‏‎ (3 revisions)
  86. Rigidity threshold‏‎ (3 revisions)
  87. Dose of record (E)‏‎ (3 revisions)
  88. Low Earth orbit‏‎ (3 revisions)
  89. Accountability‏‎ (3 revisions)
  90. X ray‏‎ (3 revisions)
  91. Half-life, physical‏‎ (3 revisions)
  92. Cell death‏‎ (3 revisions)
  93. Contamination‏‎ (3 revisions)
  94. Exponential survival curve‏‎ (3 revisions)
  95. Unsealed source‏‎ (3 revisions)
  96. Xerostomia‏‎ (3 revisions)
  97. Annual limit on intake‏‎ (3 revisions)
  98. Dose per content function‏‎ (3 revisions)
  99. Interphase death‏‎ (3 revisions)
  100. Equity‏‎ (3 revisions)
  101. Test‏‎ (3 revisions)
  102. Graded approach‏‎ (3 revisions)
  103. Public exposure‏‎ (3 revisions)
  104. Fractionation‏‎ (3 revisions)
  105. Uptake‏‎ (3 revisions)
  106. Active (red) bone marrow‏‎ (3 revisions)
  107. Utilitarian ethics‏‎ (3 revisions)
  108. Granulocyte-macrophage colony-stimulating factor‏‎ (3 revisions)
  109. Operational quantity‏‎ (3 revisions)
  110. Value judgement‏‎ (3 revisions)
  111. Granulocyte colony-stimulating factor‏‎ (3 revisions)
  112. Coster-Kronig transition‏‎ (3 revisions)
  113. Emergency preparedness‏‎ (3 revisions)
  114. Valvular heart disease‏‎ (3 revisions)
  115. Gray‏‎ (3 revisions)
  116. Personal dose equivalent‏‎ (3 revisions)
  117. Principle of justification‏‎ (3 revisions)
  118. Radiofrequency ablation‏‎ (3 revisions)
  119. Iso-effect plots‏‎ (3 revisions)
  120. Emergency procedures‏‎ (3 revisions)
  121. Lifetime risk estimates‏‎ (3 revisions)
  122. Absolute risk‏‎ (3 revisions)
  123. Virtue ethics‏‎ (3 revisions)
  124. Auger transition‏‎ (3 revisions)
  125. Bystander effect‏‎ (3 revisions)
  126. Derived air concentration‏‎ (3 revisions)
  127. Dignity‏‎ (3 revisions)
  128. Isomers‏‎ (3 revisions)
  129. Employer‏‎ (3 revisions)
  130. Activity median thermodynamic diameter‏‎ (3 revisions)
  131. Voxel phantom‏‎ (3 revisions)
  132. Radiological Protection in Healthcare‏‎ (3 revisions - redirect page)
  133. Complex tissues‏‎ (3 revisions)
  134. Growth fraction‏‎ (3 revisions)
  135. Organ dose equivalent‏‎ (3 revisions)
  136. Excretion rate (instantaneous)‏‎ (3 revisions)
  137. Extrathoracic airways‏‎ (3 revisions)
  138. Galactic cosmic radiation‏‎ (3 revisions)
  139. Growth hormone (somatotropin)‏‎ (3 revisions)
  140. ICRP Publication 103‏‎ (3 revisions)
  141. DNA damage signalling‏‎ (3 revisions)
  142. Spread-out Bragg peak‏‎ (3 revisions)
  143. Fairness‏‎ (3 revisions)
  144. Absorption‏‎ (3 revisions)
  145. Gamma ray‏‎ (3 revisions)
  146. Recovery‏‎ (3 revisions)
  147. Dose equivalent‏‎ (3 revisions)
  148. Field-size effect (Volume effect)‏‎ (3 revisions)
  149. Gastrointestinal syndrome‏‎ (3 revisions)
  150. Wisdom‏‎ (3 revisions)
  151. Biomedical research volunteer‏‎ (3 revisions)
  152. Cardiomyopathy‏‎ (3 revisions)
  153. Dose limit‏‎ (3 revisions)
  154. Target region‏‎ (3 revisions)
  155. Flexible tissues‏‎ (3 revisions)
  156. Guide to the System of Radiological Protection‏‎ (3 revisions)
  157. Autonomy‏‎ (3 revisions)
  158. Dose‏‎ (3 revisions)
  159. Dose limits‏‎ (3 revisions)
  160. Fluence‏‎ (3 revisions)
  161. Constancy test‏‎ (3 revisions)
  162. Rigidity‏‎ (2 revisions)
  163. Dose-length product‏‎ (2 revisions)
  164. Security‏‎ (2 revisions)
  165. Incident‏‎ (2 revisions)
  166. Intermediate level waste‏‎ (2 revisions)
  167. Stenosis‏‎ (2 revisions)
  168. Equieffective dose‏‎ (2 revisions)
  169. Local DRL‏‎ (2 revisions)
  170. Expanded and aligned radiation field‏‎ (2 revisions)
  171. Tolerability‏‎ (2 revisions)
  172. Medical exposure‏‎ (2 revisions)
  173. Naturally occurring radioactive material‏‎ (2 revisions)
  174. Adventitious‏‎ (2 revisions)
  175. Working level month‏‎ (2 revisions)
  176. Habitual nose breather‏‎ (2 revisions)
  177. Hypertrophic cardiomyopathy‏‎ (2 revisions)
  178. Background dose (rate)‏‎ (2 revisions)
  179. Radiosensitivity, cellular‏‎ (2 revisions)
  180. Containment‏‎ (2 revisions)
  181. Detriment‏‎ (2 revisions)
  182. Dose-rate effect‏‎ (2 revisions)
  183. Inclusiveness‏‎ (2 revisions)
  184. Source-related‏‎ (2 revisions)
  185. Internal conversion electron‏‎ (2 revisions)
  186. Electron-capture decay‏‎ (2 revisions)
  187. LD 50/30‏‎ (2 revisions)
  188. Telangiectasia‏‎ (2 revisions)
  189. Member of the public‏‎ (2 revisions)
  190. Fluoroscopically or computed tomography guided interventions‏‎ (2 revisions)
  191. Unattached fraction‏‎ (2 revisions)
  192. Necrosis‏‎ (2 revisions)
  193. Patient entrance reference point‏‎ (2 revisions)
  194. Hypoplasia‏‎ (2 revisions)
  195. Backscatter detection system‏‎ (2 revisions)
  196. Potential recoverability correction factor‏‎ (2 revisions)
  197. Bradycardia‏‎ (2 revisions)
  198. Protective action guide‏‎ (2 revisions)
  199. Radiation worker‏‎ (2 revisions)
  200. Reference air kerma‏‎ (2 revisions)
  201. Decay constant‏‎ (2 revisions)
  202. Self-help protection‏‎ (2 revisions)
  203. Individual-related‏‎ (2 revisions)
  204. Dose of record Hp (10)‏‎ (2 revisions)
  205. Electrophysiology‏‎ (2 revisions)
  206. Storage‏‎ (2 revisions)
  207. Track structure‏‎ (2 revisions)
  208. Mendelian diseases‏‎ (2 revisions)
  209. Accreditation‏‎ (2 revisions)
  210. Neurological syndrome‏‎ (2 revisions)
  211. Genomic integrity‏‎ (2 revisions)
  212. Occupational exposure‏‎ (2 revisions)
  213. Hazard‏‎ (2 revisions)
  214. Peak skin dose‏‎ (2 revisions)
  215. Bragg peak‏‎ (2 revisions)
  216. Radioactive dispersion device‏‎ (2 revisions)
  217. Radon: Units of Measure‏‎ (2 revisions)
  218. Coronary heart disease‏‎ (2 revisions)
  219. Decommissioning‏‎ (2 revisions)
  220. ICRP Task Groups on Radiological Protection in Healthcare‏‎ (2 revisions)
  221. Dose-threshold‏‎ (2 revisions)
  222. Individual decontamination‏‎ (2 revisions)
  223. Subcutaneous tissue‏‎ (2 revisions)
  224. Low dose rate‏‎ (2 revisions)
  225. Transfer compartment‏‎ (2 revisions)
  226. Mitigation‏‎ (2 revisions)
  227. Fractional absorption in the gastrointestinal tract‏‎ (2 revisions)
  228. Action Level‏‎ (2 revisions)
  229. Upper reference levels‏‎ (2 revisions)
  230. Neurovascular syndrome‏‎ (2 revisions)
  231. Health Surveillance‏‎ (2 revisions)
  232. Pelagic‏‎ (2 revisions)
  233. Basal cell‏‎ (2 revisions)
  234. Practical radiological protection culture‏‎ (2 revisions)
  235. Branching fraction‏‎ (2 revisions)
  236. Chronic exposure‏‎ (2 revisions)
  237. Radioactive source‏‎ (2 revisions)
  238. Colony‏‎ (2 revisions)
  239. Cosmic Radiation in Aviation‏‎ (2 revisions)
  240. Reference biokinetic model‏‎ (2 revisions)
  241. Decontamination‏‎ (2 revisions)
  242. Relocation‏‎ (2 revisions)
  243. Diastasis‏‎ (2 revisions)
  244. Risk coefficient‏‎ (2 revisions)
  245. Individual monitoring‏‎ (2 revisions)
  246. Dose per unit intake coefficient‏‎ (2 revisions)
  247. Source term‏‎ (2 revisions)
  248. Emergency‏‎ (2 revisions)
  249. Latent time/period or latency interval‏‎ (2 revisions)
  250. Low level waste‏‎ (2 revisions)
  251. Exposure, external or internal‏‎ (2 revisions)
  252. Graft vs host disease‏‎ (2 revisions)
  253. Air-kerma, incident‏‎ (2 revisions)
  254. Heliosphere‏‎ (2 revisions)
  255. Qualified expert‏‎ (2 revisions)
  256. Class SR-0 gases‏‎ (2 revisions)
  257. Radioactive substance‏‎ (2 revisions)
  258. Reference individual‏‎ (2 revisions)
  259. Decontamination factor‏‎ (2 revisions)
  260. Remedial action‏‎ (2 revisions)
  261. ICRPædia Guide to Dose Coefficients‏‎ (2 revisions)
  262. Dose rate‏‎ (2 revisions)
  263. Intervention Level‏‎ (2 revisions)
  264. Emergency exposure situation‏‎ (2 revisions)
  265. Substantial radiation dose level‏‎ (2 revisions)
  266. Erythropoietin‏‎ (2 revisions)
  267. Exposure (in the context of inhalation)‏‎ (2 revisions)
  268. Transfer rate‏‎ (2 revisions)
  269. Multi-detector computed tomography‏‎ (2 revisions)
  270. Fractionation and dose delivery patterns‏‎ (2 revisions)
  271. Percutaneous coronary intervention‏‎ (2 revisions)
  272. Prevailing circumstances‏‎ (2 revisions)
  273. Broad beam therapy irradiation technique‏‎ (2 revisions)
  274. Class SR-1 gases‏‎ (2 revisions)
  275. Committed effective dose‏‎ (2 revisions)
  276. Radon Recommendations for Authorities‏‎ (2 revisions)
  277. Cost-benefit analysis‏‎ (2 revisions)
  278. Reference level‏‎ (2 revisions)
  279. Remediation‏‎ (2 revisions)
  280. Dichotomous‏‎ (2 revisions)
  281. Risk of Exposure to Radon‏‎ (2 revisions)
  282. Dose rate effectiveness factor‏‎ (2 revisions)
  283. South Atlantic anomaly‏‎ (2 revisions)
  284. Interventional procedure‏‎ (2 revisions)
  285. Emergency plan‏‎ (2 revisions)
  286. Ethics‏‎ (2 revisions)
  287. Lymphatic system‏‎ (2 revisions)
  288. ALARA‏‎ (2 revisions)
  289. Transforming growth factor‏‎ (2 revisions)
  290. Hierarchical tissues‏‎ (2 revisions)
  291. Area monitoring‏‎ (2 revisions)
  292. Pericarditis‏‎ (2 revisions)
  293. Benthic‏‎ (2 revisions)
  294. Principle of application of dose limits‏‎ (2 revisions)
  295. Bronchial region‏‎ (2 revisions)
  296. Class SR-2 gases‏‎ (2 revisions)
  297. Radioactivity‏‎ (2 revisions)
  298. Committed equivalent dose‏‎ (2 revisions)
  299. Radon Recommendations for Workplaces‏‎ (2 revisions)
  300. Deontological Ethics‏‎ (2 revisions)
  301. Repopulation‏‎ (2 revisions)
  302. Differentiation‏‎ (2 revisions)
  303. Routine monitoring‏‎ (2 revisions)
  304. ICRPædia Guide to Radon‏‎ (2 revisions)
  305. Special (non-routine) monitoring‏‎ (2 revisions)
  306. Lifetime risk‏‎ (2 revisions)
  307. Macrophage colony stimulating factor‏‎ (2 revisions)
  308. Multiplicative risk projection model‏‎ (2 revisions)
  309. Activity‏‎ (2 revisions)
  310. High level waste‏‎ (2 revisions)
  311. Clearance‏‎ (2 revisions)
  312. Representative organism (non-human biota)‏‎ (2 revisions)
  313. ICRPædia Guide to the Basics of Ionising Radiation‏‎ (2 revisions)
  314. Dose constraint‏‎ (2 revisions)
  315. Early normal tissue responses‏‎ (2 revisions)
  316. Threshold dose for tissue reactions‏‎ (2 revisions)
  317. Magnetosphere‏‎ (2 revisions)
  318. Beta-minus decay‏‎ (2 revisions)
  319. Clearance level‏‎ (2 revisions)
  320. Radiographer‏‎ (2 revisions)
  321. Representative person‏‎ (2 revisions)
  322. Safety‏‎ (2 revisions)
  323. Dose conversion coefficient‏‎ (2 revisions)
  324. Edema‏‎ (2 revisions)
  325. Specific effective energy‏‎ (2 revisions)
  326. Limitation of dose‏‎ (2 revisions)
  327. Excess relative risk‏‎ (2 revisions)
  328. Exposure situation‏‎ (2 revisions)
  329. Transmission detection system‏‎ (2 revisions)
  330. Multistage tumorigenesis‏‎ (2 revisions)
  331. Non-sphericity parameter‏‎ (2 revisions)
  332. Growth factor‏‎ (2 revisions)
  333. Alimentary tract transfer factor‏‎ (2 revisions)
  334. Pharynx‏‎ (2 revisions)
  335. Beta-plus decay‏‎ (2 revisions)
  336. Calculating Doses from Intakes of Radionuclides‏‎ (2 revisions)
  337. Cumulative dose‏‎ (2 revisions)
  338. Reproductive integrity‏‎ (2 revisions)
  339. Safety case‏‎ (2 revisions)
  340. Slow repair‏‎ (2 revisions)
  341. Effect Dose 50‏‎ (2 revisions)
  342. Isotropic geometry‏‎ (2 revisions)
  343. Endogeneous excretion‏‎ (2 revisions)
  344. Lineal energy‏‎ (2 revisions)
  345. Thyroid blocking‏‎ (2 revisions)
  346. Exposure to Radon at Home‏‎ (2 revisions)
  347. Transparency‏‎ (2 revisions)
  348. GATA binding protein 2‏‎ (2 revisions)
  349. Waste disposal‏‎ (2 revisions)
  350. Non-targeted effects‏‎ (2 revisions)
  351. Hormones‏‎ (2 revisions)
  352. Authorization‏‎ (2 revisions)
  353. Procedural values‏‎ (2 revisions)
  354. Clonogenic cells‏‎ (2 revisions)
  355. Curie‏‎ (2 revisions)
  356. Cytokines‏‎ (2 revisions)
  357. Residual dose‏‎ (2 revisions)
  358. Safety culture‏‎ (2 revisions)
  359. Solar cosmic radiation‏‎ (2 revisions)
  360. Inhalability‏‎ (2 revisions)
  361. Spontaneous fission‏‎ (2 revisions)
  362. Itinerant (radiation) worker‏‎ (2 revisions)
  363. Linear-non-threshold model‏‎ (2 revisions)
  364. Trapped particles‏‎ (2 revisions)
  365. Acute radiation syndrome‏‎ (2 revisions)
  366. Orphan source‏‎ (2 revisions)
  367. Hounsfield unit‏‎ (2 revisions)
  368. Authorized limit‏‎ (2 revisions)
  369. Planned exposure situation‏‎ (2 revisions)
  370. Progenitor cell‏‎ (2 revisions)
  371. Cardiac arrhythmias‏‎ (2 revisions)
  372. Radiation belt‏‎ (2 revisions - redirect page)
  373. Clonogenic survival‏‎ (2 revisions)
  374. Reasonableness‏‎ (2 revisions)
  375. Respiratory protection‏‎ (2 revisions)
  376. Disposal‏‎ (2 revisions)
  377. Scintigraphy‏‎ (2 revisions)
  378. Dose criteria‏‎ (2 revisions)
  379. Solar cycle‏‎ (2 revisions)
  380. Inner bremsstrahlung‏‎ (2 revisions)
  381. Environmental exposure‏‎ (2 revisions)
  382. Systemic model‏‎ (2 revisions)
  383. Linear-quadratic dose response model‏‎ (2 revisions)
  384. Exempt waste‏‎ (2 revisions)
  385. Time factor‏‎ (2 revisions)
  386. Myocardial perfusion‏‎ (2 revisions)
  387. Adaptive response‏‎ (2 revisions)
  388. What is Radon?‏‎ (2 revisions)
  389. Alveolar-interstitial region‏‎ (2 revisions)
  390. Autoimmune disease‏‎ (2 revisions)
  391. Platelet-derived growth factor‏‎ (2 revisions)
  392. ICRP Publication 118‏‎ (2 revisions)
  393. Cardiac valve diseases‏‎ (2 revisions)
  394. Radiation modifier‏‎ (2 revisions)
  395. Radiological protection principles‏‎ (2 revisions)
  396. DRL process‏‎ (2 revisions)
  397. Retrievability‏‎ (2 revisions)
  398. Immune system‏‎ (2 revisions)
  399. Institutional control‏‎ (2 revisions)
  400. Stakeholder‏‎ (2 revisions)
  401. Environmental radiation protection‏‎ (2 revisions)
  402. Tachycardia‏‎ (2 revisions)
  403. Exemption level‏‎ (2 revisions)
  404. Tissue equivalent material‏‎ (2 revisions)
  405. Myocardial stress test‏‎ (2 revisions)
  406. Oversight‏‎ (2 revisions)
  407. Projected dose‏‎ (2 revisions)
  408. Co-expertise‏‎ (2 revisions)
  409. Radionuclides of natural origin‏‎ (2 revisions)
  410. Connective tissue‏‎ (2 revisions)
  411. Recovery (cellular or tissue)‏‎ (2 revisions)
  412. Reversibility‏‎ (2 revisions)
  413. In vivo radiobioassay‏‎ (2 revisions)
  414. Solar particle event‏‎ (2 revisions)
  415. Effective dose equivalent‏‎ (2 revisions)
  416. Existing exposure situation‏‎ (2 revisions)
  417. Gastroschisis‏‎ (2 revisions)
  418. Worker‏‎ (2 revisions)
  419. Nuclear track detectors‏‎ (2 revisions)
  420. Angiogenesis‏‎ (2 revisions)
  421. Hyperbaric oxygen‏‎ (2 revisions)
  422. Bioturbation‏‎ (2 revisions)
  423. Cardioverter-defibrillator‏‎ (2 revisions)
  424. Radiation safety officer‏‎ (2 revisions)
  425. Radioresponsiveness‏‎ (2 revisions)
  426. Consequential late effects‏‎ (2 revisions)
  427. Recovery responder‏‎ (2 revisions)
  428. DRL value‏‎ (2 revisions)
  429. Rehabilitation of living conditions‏‎ (2 revisions)
  430. Right to know‏‎ (2 revisions)
  431. Incidence‏‎ (2 revisions)
  432. Solar wind‏‎ (2 revisions)
  433. Epithelium‏‎ (2 revisions)
  434. Target tissue‏‎ (2 revisions)
  435. Measuring and Reducing Radon Levels in your Home‏‎ (2 revisions)
  436. Acceptance test‏‎ (2 revisions)
  437. Gastrulation‏‎ (2 revisions)
  438. Working level‏‎ (2 revisions)
  439. OLINDA/EXM‏‎ (2 revisions)
  440. Habitual mouth breather‏‎ (2 revisions)
  441. Annihilation photons‏‎ (2 revisions)
  442. Particle radiance‏‎ (2 revisions)
  443. Hyperfractionation‏‎ (2 revisions)
  444. Bone marrow‏‎ (2 revisions)
  445. Protection strategy‏‎ (2 revisions)
  446. Radiation source‏‎ (2 revisions)
  447. Cohort study‏‎ (2 revisions)
  448. Radiosensitiser‏‎ (2 revisions)
  449. ICRP Publication 25‏‎ (1 revision)
  450. Relative biological effectiveness‏‎ (1 revision)
  451. ICRP Publication 31‏‎ (1 revision)
  452. Deterministic effect‏‎ (1 revision)
  453. ICRP Publication 98‏‎ (1 revision)
  454. ICRP Publication 46‏‎ (1 revision)
  455. ICRP Publication 60‏‎ (1 revision)
  456. Dose modifying factor‏‎ (1 revision)
  457. Somatic effect‏‎ (1 revision)
  458. ICRP Publication 75‏‎ (1 revision)
  459. ICRP Publication 9‏‎ (1 revision)
  460. Targeted effects‏‎ (1 revision)
  461. 1934 Recommendations‏‎ (1 revision)
  462. Access control‏‎ (1 revision)
  463. Typical value‏‎ (1 revision)
  464. General Information: Radon‏‎ (1 revision - redirect page)
  465. Particle transport‏‎ (1 revision)
  466. ICRP Publication 108‏‎ (1 revision)
  467. Brachytherapy‏‎ (1 revision)
  468. ICRP Publication 121‏‎ (1 revision)
  469. Case–control study‏‎ (1 revision)
  470. ICRP Publication 136‏‎ (1 revision)
  471. Collective dose‏‎ (1 revision)
  472. ICRP Publication 150‏‎ (1 revision)
  473. Reference Person‏‎ (1 revision)
  474. ICRP Publication 26‏‎ (1 revision)
  475. DS86‏‎ (1 revision)
  476. Relative life lost‏‎ (1 revision)
  477. ICRP Publication 32‏‎ (1 revision)
  478. ICRP Publication 99‏‎ (1 revision)
  479. ICRP Publication 47‏‎ (1 revision)
  480. Security screening‏‎ (1 revision)
  481. ICRP Publication 61‏‎ (1 revision)
  482. ICRP Publication 76‏‎ (1 revision)
  483. Stochastic effect‏‎ (1 revision)
  484. Equilibrium equivalent concentration‏‎ (1 revision)
  485. Expanded radiation field‏‎ (1 revision)
  486. 1937 Recommendations‏‎ (1 revision)
  487. Tolerance dose‏‎ (1 revision)
  488. Adventitious source‏‎ (1 revision)
  489. Occupancy factor‏‎ (1 revision)
  490. Annual intake‏‎ (1 revision)
  491. ICRP Publication 109‏‎ (1 revision)
  492. ICRP Publication 122‏‎ (1 revision)
  493. ICRP Publication 137‏‎ (1 revision)
  494. Radon-prone area‏‎ (1 revision)
  495. ICRP Publication 151‏‎ (1 revision)
  496. ICRP Publication 27‏‎ (1 revision)
  497. Relative risk‏‎ (1 revision)
  498. ICRP Publication 33‏‎ (1 revision)
  499. Detriment-adjusted risk‏‎ (1 revision)
  500. Ring chromosome‏‎ (1 revision)

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)